Listing 13.19 Liver, Gallbladder, and Bile Duct Cancer in 2026

Cancers of the liver and biliary tract cause enormous morbidity and mortality in the United States. The American Cancer Society projects 41,630 new liver and intrahepatic bile duct cancer cases (28,220 men, 13,410 women) with 29,840 deaths in 2026. Gallbladder cancer projects 12,190 new cases with 4,310 deaths. Extrahepatic bile duct cancers (perihilar Klatskin tumors and distal cholangiocarcinoma) add several thousand more cases.

SSA Listing 13.19 covers hepatocellular carcinoma (HCC), intrahepatic and extrahepatic cholangiocarcinoma, gallbladder cancer, and other primary malignancies of the liver and biliary tract. HCC is on the Compassionate Allowance list. Cholangiocarcinoma has undergone a treatment revolution over the past 5 years with the arrival of FGFR2 inhibitors, IDH1 inhibitors, and immunotherapy combinations. This walkthrough covers the listing paragraphs, staging systems (BCLC, MELD, Child-Pugh), modern therapy, and post-treatment residuals.

The listing text

Paragraph A: Any hepatocellular carcinoma

Any hepatocellular carcinoma qualifies under 13.19A regardless of stage. The rationale is that HCC almost always arises in cirrhotic livers with limited functional reserve, and the combination of cancer plus advanced liver disease is severely disabling. Even stage I HCC in a cirrhotic patient has meaningful mortality risk.

Paragraph B: Other liver malignancies (cholangiocarcinoma, angiosarcoma, hepatoblastoma) and gallbladder/bile duct cancer

Cholangiocarcinoma, gallbladder cancer, extrahepatic bile duct cancer, and rare primary liver tumors qualify when:

• Inoperable, unresectable, or locally advanced
• Recurrent after prior treatment
• Metastatic to regional nodes or distant sites

Small early-stage cholangiocarcinoma or gallbladder cancer identified incidentally at cholecystectomy and cured by simple resection with negative margins may not meet 13.19 unless recurrence occurs.

Hepatocellular carcinoma (HCC)

Etiology and background

HCC arises in cirrhotic livers about 90% of the time. Major risk factors:

• Chronic hepatitis B (highest per-capita worldwide, remaining major factor in US Asian populations)
• Chronic hepatitis C (leading US cause historically, declining with DAA treatment)
• Alcohol-related cirrhosis
• Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) with cirrhosis - now the fastest-growing HCC etiology
• Hemochromatosis
• Alpha-1 antitrypsin deficiency
• Aflatoxin exposure
• Cryptogenic cirrhosis

Staging: BCLC (Barcelona Clinic Liver Cancer)

Standard staging system integrating tumor burden, liver function (Child-Pugh), and performance status:

• BCLC 0: single lesion under 2 cm, Child A, PS 0 - very early
• BCLC A: single lesion or up to 3 lesions each under 3 cm, Child A-B, PS 0 - early
• BCLC B: multinodular disease exceeding Milan criteria, Child A-B, PS 0 - intermediate
• BCLC C: portal vein invasion or extrahepatic spread, Child A-B, PS 1-2 - advanced
• BCLC D: any tumor, Child C or PS 3-4 - terminal

Milan and UCSF criteria for transplant

Milan: 1 lesion up to 5 cm, or 2-3 lesions each up to 3 cm, without vascular invasion or extrahepatic disease. UCSF: expanded to include 1 lesion up to 6.5 cm or 2-3 lesions each up to 4.5 cm with total diameter up to 8 cm. Both aim to select HCC patients likely to benefit from transplant.

Cholangiocarcinoma subtypes

Intrahepatic cholangiocarcinoma (iCCA)

Arises above the second-order bile ducts within the liver. Presents like a hepatic mass. About 10-15% of primary liver cancers. Rising incidence globally. Actionable molecular alterations found in 40-50%:

• FGFR2 fusions/rearrangements (10-15%, pemigatinib, futibatinib, infigratinib)
• IDH1 mutations (10-15%, ivosidenib)
• BRAF V600E (5%, dabrafenib + trametinib)
• HER2 amplification (5%, trastuzumab + pertuzumab)
• NTRK fusions (rare, larotrectinib/entrectinib)
• MSI-high (rare, pembrolizumab)

Perihilar cholangiocarcinoma (Klatskin tumor)

At bifurcation of right and left hepatic ducts. Bismuth-Corlette classification (I-IV) describes extent. Surgery involves major hepatectomy + extrahepatic bile duct resection with Roux-en-Y hepaticojejunostomy. Perihilar tumors are the least likely to be resectable.

Distal cholangiocarcinoma

In the distal common bile duct. Treated with Whipple procedure. Better resectability rates than perihilar.

Gallbladder cancer

Often incidentally found at cholecystectomy for gallstones. Adenocarcinoma predominant. High-risk features: T1b or higher, positive margins, elevated CA 19-9. Radical cholecystectomy (partial hepatectomy of segments IVb/V + portal lymphadenectomy) for T1b+ tumors.

Diagnostic evidence required

• Imaging: CT abdomen/pelvis with contrast (arterial + portal venous + delayed phases), MRI with hepatobiliary contrast (gadoxetate), MRCP for biliary anatomy, PET-CT for distant staging
• HCC-specific: LI-RADS (Liver Imaging Reporting and Data System) category. LI-RADS 5 lesions in high-risk patients (cirrhosis, chronic HBV) can be diagnosed without biopsy.
• Pathology for cholangiocarcinoma and gallbladder cancer (mandatory), and for HCC when imaging inconclusive
• Serum markers: AFP (alpha-fetoprotein) for HCC (elevated in 60-70%), CA 19-9 for cholangiocarcinoma, CEA
• Liver function: bilirubin, INR, albumin, MELD score, Child-Pugh score, platelet count
• Hepatitis serologies: HBV surface antigen, anti-HCV, HBV DNA if positive HBsAg
• Molecular testing for cholangiocarcinoma: comprehensive genomic profiling to identify actionable alterations

The Compassionate Allowance overlay

Hepatocellular carcinoma is on the CAL list. All HCC cases automatically flag for expedited processing (14-30 days initial decision). Cholangiocarcinoma and gallbladder cancer with metastases are also on CAL.

Modern treatment for HCC

Atezolizumab + bevacizumab (IMbrave150)

First-line for unresectable/advanced HCC since 2020. Median OS 19.2 months in IMbrave150. Requires screening endoscopy to rule out esophageal varices before bevacizumab. Toxicities: hypertension, proteinuria, bleeding, checkpoint inhibitor irAEs.

Durvalumab + tremelimumab STRIDE regimen (HIMALAYA)

Alternative first-line combining PD-L1 inhibitor with single priming dose of CTLA-4 inhibitor. Approved 2022. Toxicities: irAEs similar to other IO combinations but with lower CTLA-4 exposure than continuous ipilimumab.

Lenvatinib, sorafenib

Multi-kinase TKIs used as second-line or in IO-ineligible patients. Toxicities: hypertension, diarrhea, fatigue, hand-foot syndrome, thyroid dysfunction.

Regorafenib, cabozantinib, ramucirumab

Later-line options.

Locoregional therapy

Transarterial chemoembolization (TACE) for BCLC B intermediate disease. Transarterial radioembolization (TARE) with Y-90 for advanced HCC. Radiofrequency ablation (RFA) for small lesions.

Liver transplantation

Curative for select HCC within Milan/UCSF criteria. Locoregional therapy used as bridging while on transplant waitlist. Post-transplant residuals fall under Listing 5.09 (see our liver transplant walkthrough).

Modern treatment for cholangiocarcinoma

Gemcitabine + cisplatin + durvalumab (TOPAZ-1)

New first-line standard for advanced biliary tract cancers since 2022. Combined chemotherapy + IO. Improved OS vs gem/cis alone.

Gemcitabine + cisplatin + pembrolizumab (KEYNOTE-966)

Alternative first-line combination for advanced biliary tract cancer, approved 2023.

Targeted therapy for iCCA

• Pemigatinib, futibatinib, infigratinib for FGFR2 fusion-positive iCCA (second-line)
• Ivosidenib for IDH1-mutated iCCA (second-line)
• Dabrafenib + trametinib for BRAF V600E
• Trastuzumab + pertuzumab for HER2 amplification

Post-hepatectomy and post-cystectomy residuals

Major hepatectomy

Right hepatectomy or extended right/left hepatectomy for HCC or cholangiocarcinoma. Residuals: post-hepatectomy liver failure (5-10%), biliary leaks, chronic ascites if borderline function, wound complications, portal vein thrombosis. Long-term liver function usually recovers if adequate remnant.

Whipple for distal cholangiocarcinoma or gallbladder cancer

Same residuals as pancreatic Whipple. See our pancreatic cancer walkthrough for detail.

Radical cholecystectomy with liver segmentectomy

Chronic incisional pain, adhesions, biliary complications.

Worked case examples

Case 1: David, 64, California, HCC on hepatitis C cirrhosis, BCLC C

David had chronic hepatitis C diagnosed 2010, achieved SVR with DAA in 2018 but had established cirrhosis. Surveillance ultrasound January 2026 showed new 5 cm liver mass. Multiphase CT: LI-RADS 5, portal vein branch invasion. AFP 4,500. Child-Pugh A. BCLC C.

SSDI application filed February 2026. CAL for HCC triggered. Approved 9 days at California DDS. Started atezolizumab + bevacizumab per IMbrave150. Screened endoscopically first, small varices banded. Partial response at 3 months. Later progressed, switched to lenvatinib.

Case 2: Sarah, 58, Illinois, FGFR2 fusion iCCA on pemigatinib

Sarah presented with progressive right upper quadrant pain and weight loss in March 2026. CT abdomen: 8 cm right hepatic mass with satellite lesions and retroperitoneal adenopathy. Biopsy: intrahepatic cholangiocarcinoma. Molecular testing: FGFR2-BICC1 fusion.

SSDI application filed April 2026. CAL for cholangiocarcinoma with metastases. Approved 11 days at Illinois DDS. First-line gemcitabine + cisplatin + durvalumab, then progression at 6 months. Second-line pemigatinib with ongoing partial response.

Case 3: Angela, 71, Florida, incidentally found T2 gallbladder cancer on cholecystectomy

Angela had elective laparoscopic cholecystectomy for symptomatic gallstones March 2026. Final pathology: T2 gallbladder adenocarcinoma with lymphovascular invasion. Underwent completion radical cholecystectomy (partial hepatectomy segments IVb/V + portal lymphadenectomy) June 2026. Final: T2N1 with 2 of 8 nodes positive.

SSDI application filed July 2026. Listing 13.19B met (regional nodal disease). Approved 4 weeks at Florida DDS. Adjuvant capecitabine + oxaliplatin per BILCAP-adjacent regimen.

What to file with your application

1. Multiphase CT/MRI abdomen with pancreatic and hepatobiliary protocols
2. MRCP for biliary anatomy
3. Pathology report or LI-RADS 5 imaging for HCC diagnosis
4. AFP and CA 19-9 levels
5. Hepatitis serologies (HBsAg, anti-HCV, HBV DNA)
6. Liver function panel with MELD and Child-Pugh calculation
7. Molecular testing for cholangiocarcinoma (FGFR2, IDH1, BRAF, HER2, NTRK, MSI)
8. Oncology consultation notes with BCLC or TNM staging and treatment plan
9. Documentation of any locoregional or systemic therapy
10. Transplant evaluation status if applicable

Related reading

Full section walkthrough: Section 13.00 cancer basics. Related listing: 5.09 liver transplantation. Other cancer listings: 13.20 pancreatic, 13.18 colorectal, 13.21 kidney/bladder.

Frequently asked questions

Next steps

If you were diagnosed with HCC, cholangiocarcinoma, or gallbladder cancer, file for SSDI immediately after diagnosis confirmation. HCC has automatic CAL. Advanced biliary tract cancers with metastases also qualify for CAL fast-track.